贝伐单抗联合卡培他滨一线治疗老年转移性结直肠癌患者的疗效和安全性

Effect and safety of bevacizumab combined with capecitabine in the treatment of elderly patients with metastatic colorectal cancer

目的:评估贝伐单抗和卡培他滨的联合方案在老年转移性结直肠癌(metastatic colon or rectal cancer,m CRC)患者一线治疗中的疗效和安全性。方法:收集2013年1月至2016年12月入住首都医科大学附属北京友谊医院76例使用贝伐单抗(5~7.5 mg/kg,d1,q3w)联合卡培他滨(1 000~1 250 mg/m2,bid,d 1~1 4,q 3 w)一线治疗老年m CRC的病例进行分析,分析疗效及不良反应(adverse event s,AE)。结果:经贝伐单抗联合卡培他滨方案治疗,患者总体有效率为36%,疾病控制率为73%;中位无进展生存期和总生存期分别为10.6个月和18.2个月;39例(51%)患者发生3/4级AE,最常见的为手足综合征(18%)、腹泻(10%)和深静脉血栓形成(7%);4名患者因治疗相关的AE死亡。结论:对于不适合接受多药联合化疗的老年患者,贝伐单抗联合卡培他滨是一种有效的治疗选择。

Objective： To evaluate the efficacy and safety ofbevacizumab and capecitabine in the first-line treatment of elderly patients with metastatic colorectal cancer （mCRC）. Methods： A total of 76 elderly patients with metastatic colorectal cancer first-line treated with （5-7.5 mg/kg, d 1, q3w） combined with capecitabine （1 000-1 250 mg/m2, bid, d1-14, q3w） between January 2013 and December 2016 were collected. The efficacy and adverse events （AEs） were carefully analyzed. Results： After treated with bevacizumab combined with capecitabine, the overall effective rate was 36% and the disease control rate was 73%. The median progression-free survival and overall survival were 10.6 months and 18.2 months, respectively; 39 patients （51%） developed grade 3 and 4 AE, the most common were hand-foot syndrome （18%）, diarrhea （10%） and deep vein thrombosis （7%）; four patients died due to treatment-related adverse events. Conclusion： For elderly mCRC patients who are not eligible for multidrug chemotherap）5 bevacizumab combined with capecitabine is an effective treatment option.